Delving into the Latest Updates on Mitolactol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bromoalcohol, DBD, Dibromdicil

+ [8]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication

Brain CancerUterine Cervical Cancer

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC6H12Br2O4

InChIKeyVFKZTMPDYBFSTM-GUCUJZIJSA-N

CAS Registry10318-26-0

To evaluate EC/TC (epirubicin and cyclophosphomide or docetaxel and cyclophosphomide) with EC/TC plus DBD (Danggui Buxue Decoction) in adjuvant treatment of breast cancer patients. The aim is to evaluate whether DBD can decrease the incidence of grade 3/4 neutropenia induced by EC/TC regimen during chemotherapy.

Start Date01 Oct 2013

Sponsor / Collaborator

Shanghai Jiao Tong University

NCT00002620 / CompletedPhase 3

EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas.
PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy in treating patients with anaplastic astrocytomas.

Start Date01 Nov 1994

Sponsor / Collaborator

Eortc

100 Clinical Results associated with Mitolactol

Login to view more data

100 Translational Medicine associated with Mitolactol

Login to view more data

100 Patents (Medical) associated with Mitolactol

Login to view more data

264

Literatures (Medical) associated with Mitolactol

01 Mar 2024·American Journal of Transplantation

Association of procurement technique with organ yield and cost following donation after circulatory death

Article

Author: Cain, Michael T ; Nydam, Trevor L ; Bakhtiyar, Syed Shahyan ; Rove, Jessica Y ; Gutowski, John ; Reece, T Brett ; Bababekov, Yanik J ; Schold, Jesse D ; Cleveland, Joseph C ; Hoffman, Jordan R H ; Park, Sarah Y ; Maksimuk, Tiffany E ; Pomposelli, James J ; Pomfret, Elizabeth A

Donation after circulatory death (DCD) could account for the largest expansion of the donor allograft pool in the contemporary era. However, the organ yield and associated costs of normothermic regional perfusion (NRP) compared to super-rapid recovery (SRR) with ex-situ normothermic machine perfusion, remain unreported. The Organ Procurement and Transplantation Network (December 2019 to June 2023) was analyzed to determine the number of organs recovered per donor. A cost analysis was performed based on our institution's experience since 2022. Of 43 502 donors, 30 646 (70%) were donors after brain death (DBD), 12 536 (29%) DCD-SRR and 320 (0.7%) DCD-NRP. The mean number of organs recovered was 3.70 for DBD, 3.71 for DCD-NRP (P < .001), and 2.45 for DCD-SRR (P < .001). Following risk adjustment, DCD-NRP (adjusted odds ratio 1.34, confidence interval 1.04-1.75) and DCD-SRR (adjusted odds ratio 2.11, confidence interval 2.01-2.21; reference: DBD) remained associated with greater odds of allograft nonuse. Including incomplete and completed procurement runs, the total average cost of DCD-NRP was $9463.22 per donor. By conservative estimates, we found that approximately 31 donor allografts could be procured using DCD-NRP for the cost equivalent of 1 allograft procured via DCD-SRR with ex-situ normothermic machine perfusion. In conclusion, DCD-SRR procurements were associated with the lowest organ yield compared to other procurement methods. To facilitate broader adoption of DCD procurement, a comprehensive understanding of the trade-offs inherent in each technique is imperative.

01 Mar 2024·Heliyon

Dang-Gui-Bu-Xue decoction improves wound healing in diabetic rats by the activation of Notch signaling

Article

Author: Zhang, Xian ; Yang, Zhiwei ; Zhao, Xiaogui ; Wang, Xiaodan ; Zhao, Song

Diabetes serves as a severe chronic disease that severely affects the normal life of human beings. Diabetes causes the complication of diabetic wound dysfunction, which is characterized by sustained inflammation, altered angiogenesis, delayed epithelialization and abnormal secretion of protease. Dang-Gui-Bu-Xue decoction (DBD) is a Chinese traditional medicine that comprises Radix Astragali and Radix Angelicae sinensis and is widely applied in treatment of multiple diseases owing to its functions against inflammation, lipid peroxidation and oxidative stress. Nevertheless, the impact of DBD on diabetic wound healing remains elusive. In this study, we aimed to explore the function of DBD in the regulation of wound healing. We observed that the gavage administration of DBD reduced the wound area, inflammatory infiltration, inflammatory factor levesl, and enhanced granulation tissue formation, wound extracellular matrix (ECM) production, and CD31 accumulation in the diabetic rat wound model, and the co-treatment of gavage administration and the external administration of gauze containing DBD further improved the wound healing effect, while the combination of Notch signaling inhibitor DAPT ((N- [N- (3, 5-difluorophenacetyl)-l-alanyl]-s-phenylglycinet-butyl ester)) could attenuate the improvement. Regarding to the mechanism, the expression levels of Notch1, Delta-like canonical Notch ligand 4 (Dll4), Jagged1, and Hairy Enhancer of Split-1 (Hes1) were increased by DBD, while the treatment of DAPT impaired the effect in the rats. Furthermore, we found that the high glucose (HG)-inhibited viability and tube formation were induced by DBD in human umbilical vein endothelial cells (HUVECs), in which DAPT could reverse this effect. Therefore, we concluded that DBD contributed to wound healing by the activation of Notch signaling. Our finding provides new insight into the potential role of DBD in promoting diabetic wound healing.

01 Jan 2024·Methods in Molecular Biology

DBD-FISH Using Specific Chromosomal Region Probes for the Study of Cervical Carcinoma Progression

Review

Author: García-Vielma, Catalina ; Cortés-Gutiérrez, Elva I ; Gosálvez, Jaime ; Dávila-Rodríguez, Martha I ; Fernández, José L

Genomic instability is an important biomarker in the progression of cervical carcinoma. DBD-FISH (DNA breakage detection-fluorescence in situ hybridization) is a sensitive method that detects strand breaks, alkali-labile sites, and incomplete DNA excision repair in cells of the cervical epithelium. This technique integrates the microgel immersion of cells from a vaginal lesion scraping and the DNA unwinding treatment with the capacity of FISH integrated into digital image analysis. Cells captured within an agarose matrix are lysed and submerged in an alkaline unwinding solution that generates single-stranded DNA motifs at the ends of internal DNA strand breaks. After neutralization, the microgel is dehydrated and the cells are incubated with DNA-labeled probes. The quantity of a hybridized probe at a target sequence corresponds to the measure of the single-stranded DNA produced during the unwinding step, which is equivalent to the degree of local DNA breakage. DNA damage does not show uniformly throughout the entire DNA of a cell; rather, it is confined to specific chromosomal sites. In this chapter, an overview of the technique is supplied, focusing on its ability for assessing the association between DNA damage in specific sequences and in the progressive stages of cervical carcinoma.

100 Deals associated with Mitolactol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XX	DB12916

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Cancer	Phase 1	US	-	-
Neoplasms	Phase 1	IE	-	-
Neoplasms	Phase 1	GB	-	-
Uterine Cervical Cancer	Phase 1	US	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00002620 (Pubmed \| Neurology)	Phase 3	Glioma Adjuvant	269	Radiation therapy + DBD + BCNU	(wgzlilvvoy) = bcxyrozfxi xvfprnrbdd (risdcyyluw ) View more	Positive	01 Aug 1994
				Radiation therapy alone	(wgzlilvvoy) = ouvovhihww xvfprnrbdd (risdcyyluw ) View more